| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| GADICKE ANSBERT | 10%+ Owner | C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON | /s/ Ansbert Gadicke, Manager of MPM Oncology Innovations Fund GP LLC, the GP of MPM Oncology Innovations Fund, L.P. | 06 Nov 2025 | 0001134655 |
| MPM ONCOLOGY INNOVATIONS FUND LP | 10%+ Owner | C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON | /s/ Ansbert Gadicke, Manager of MPM Oncology Innovations Fund GP LLC | 06 Nov 2025 | 0001719960 |
| UBS Oncology Impact Fund L.P. | 10%+ Owner | C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON | /s/ Ansbert Gadicke, Managing Partner of MPM BioImpact LLC | 06 Nov 2025 | 0001691428 |
| Oncology Impact Fund (Cayman) Management L.P. | 10%+ Owner | C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON | /s/ Ansbert Gadicke, member of MPM Asset Management LLC | 06 Nov 2025 | 0001721036 |
| MPM BioImpact LLC | 10%+ Owner | C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON | /s/ Ansbert Gadicke | 06 Nov 2025 | 0001687078 |
| MPM Oncology Innovations Fund GP LLC | 10%+ Owner | C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON | /s/ Ansbert Gadicke, Managing Partner of MPM BioImpact LLC, the GP of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund, L.P. | 06 Nov 2025 | 0001857903 |
| MPM ASSET MANAGEMENT LLC | 10%+ Owner | C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON | /s/ Ansbert Gadicke, Managing Partner of MPM BioImpact LLC, the GP of Oncology Impact Fund (Cayman) Management L.P. | 06 Nov 2025 | 0001263048 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | HOWL | Common Stock | Sale | -$171K | -140K | -2.29% | $1.22 | 6.01M | 04 Nov 2025 | See Footnote | F1, F2, F3, F4, F5 |
| transaction | HOWL | Common Stock | Sale | -$58.5K | -48K | -0.8% | $1.22 | 5.96M | 05 Nov 2025 | See Footnote | F1, F6, F7, F8 |
| transaction | HOWL | Common Stock | Sale | -$65.9K | -54.5K | -0.91% | $1.21 | 5.9M | 06 Nov 2025 | See Footnote | F1, F9, F10, F11 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025. |
| F2 | The shares were sold as follows: 9,645 by MPM Asset Management LLC ("AM LLC"), 60,937 by MPM BioVentures 2014, L.P. ("BV 2014"), 4,064 by MPM BioVentures 2014(B), L.P. (BV 2014(B), 2,098 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 13,420 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 50,324 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. |
| F3 | MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.17 to $1.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F5 | The shares are held as follows: 412,556 by AM LLC, 2,605,487 by BV 2014, 173,782 by BV 2014(B), 89,680 by AM BV2014, 571,690 by MPM OIF and 2,153,927 by UBS Oncology. |
| F6 | The shares were sold as follows: 3,292 by AM LLC, 20,798 by BV 2014, 1,387 by BV 2014(B), 717 by AM BV2014, 4,580 by MPM OIF and 17,176 by UBS Oncology. |
| F7 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.19 to $1.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F8 | The shares are held as follows: 409,264 by AM LLC, 2,584,689 by BV 2014, 172,395 by BV 2014(B), 88,963 by AM BV2014, 567,110 by MPM OIF and 2,136,751 by UBS Oncology. |
| F9 | The shares were sold as follows: 3,738 by AM LLC, 23,619 by BV 2014, 1,575 by BV 2014(B), 814 by AM BV2014, 5,201 by MPM OIF and 19,505 by UBS Oncology. |
| F10 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.185 to $1.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F11 | The shares are held as follows: 405,526 by AM LLC, 2,561,070 by BV 2014, 170,820 by BV 2014(B), 88,149 by AM BV2014, 561,909 by MPM OIF and 2,117,246 by UBS Oncology. |
This filing is 1 of 2 identical filings due to limitations on number of Reporting Persons. See Form 4 filed by MPM BioVentures 2014, L.P.